Four Am Law 100 firms are facing off in a takeover fight involving Endo International’s unsolicited $2.2 billion cash-and-stock bid to buy Auxilium Pharmaceuticals.
The proposed transaction would scuttle Auxilium’s proposed $345 million acquisition earlier this summer of Canadian biotechnology firm QLT, a deal that would allow Auxilium to redomicile itself north of the border. On Wednesday, the Chesterbrook, Pa.-based Auxilium adopted a poison pill to fend off Endo.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
